The delisting notice from Nasdaq is a significant negative event for Allarity Therapeutics, as it indicates non-compliance with listing requirements. Although the company plans to appeal, the uncertainty surrounding the outcome is likely to negatively impact investor sentiment and the stock price in the short term.